Analysts Set Precigen, Inc. (NASDAQ:PGEN) Price Target at $7.00

Precigen, Inc. (NASDAQ:PGEN - Get Free Report) has received a consensus rating of "Moderate Buy" from the five analysts that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $7.00.

Several brokerages recently issued reports on PGEN. HC Wainwright reissued a "buy" rating and issued a $6.00 price target (up previously from $4.00) on shares of Precigen in a report on Thursday, January 23rd. JMP Securities reissued a "market outperform" rating and set a $5.00 price target on shares of Precigen in a report on Tuesday, January 14th.

Precigen Trading Up 3.4 %

Precigen stock traded up $0.06 during mid-day trading on Tuesday, reaching $1.80. The company's stock had a trading volume of 1,134,276 shares, compared to its average volume of 2,037,644. Precigen has a twelve month low of $0.65 and a twelve month high of $2.17. The business has a 50 day moving average price of $1.53 and a 200-day moving average price of $1.12. The firm has a market cap of $527.16 million, a price-to-earnings ratio of -3.27 and a beta of 1.57.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Iridian Asset Management LLC CT raised its stake in shares of Precigen by 38.8% during the fourth quarter. Iridian Asset Management LLC CT now owns 5,241,922 shares of the biotechnology company's stock valued at $5,871,000 after purchasing an additional 1,465,962 shares in the last quarter. LexAurum Advisors LLC raised its position in shares of Precigen by 151.9% during the 4th quarter. LexAurum Advisors LLC now owns 691,544 shares of the biotechnology company's stock worth $775,000 after buying an additional 417,055 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Precigen by 4.8% in the 3rd quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company's stock worth $3,075,000 after acquiring an additional 149,829 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Precigen by 11.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,222,850 shares of the biotechnology company's stock valued at $1,158,000 after acquiring an additional 127,467 shares in the last quarter. Finally, HighTower Advisors LLC increased its stake in shares of Precigen by 186.8% during the third quarter. HighTower Advisors LLC now owns 192,144 shares of the biotechnology company's stock valued at $179,000 after acquiring an additional 125,145 shares during the period. Institutional investors own 33.51% of the company's stock.

Remove Ads

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.